Huntsville, AL – CFD Research is excited to announce the formation of Kalm Therapeutics (Kalm Tx) to bring a much-needed non-steroidal eczema treatment to patients with mild to moderate atopic dermatitis (~16M Americans). Kalm Tx has emerged as an independent entity, stemming from the innovative research and development efforts of CFD Research. Kalm’s controlled release eczema wrap (CREW) utilizes the proprietary Continuous Dose technology to deliver an easier-to-use and natural eczema treatment to patients. CREW delivers its eczema-relieving compound over 24 hours, which is an improvement on topical steroids requiring 3-5 applications per day.
“This technology was developed as part of a NIH SBIR Project with the goal of giving patients a safer, easier to use, first-line eczema treatment.”, said AJ Singhal, Drug Discovery Manager at CFD Research Corporation.
In conjunction with the company formation, Mr. Chris Seibert was recruited to serve as CEO for the new venture. Mr. Seibert has previous Executive-level experience at public companies Stereotaxis and Titan Medical. At Titan Medical he led the clinical and business development efforts to develop a single port robotic platform that eventually licensed IP to Medtronic, Intuitive Surgical and Auris Health (J&J), all market leaders in the laparoscopic and robotic surgical fields.
“Kalm Therapeutics is focused on developing single use patches to naturally treat eczema and eventually other common skin conditions.” said Chris Seibert, CEO of Kalm Therapeutics. “Our patent pending Controlled Release Eczema Wrap (CREW) addresses a vital gap in the treatment paradigm of this life-altering disease that affects over 10% of the global population. I am excited to be leading this new venture as we bring a natural alternative to market.”
“After several years of R&D it is rewarding to see our innovations reach the market and make a difference in the lives of eczema patients through the formation of Kalm Therapeutics,” said Sameer Singhal, CFD Research’s President & CEO.
ABOUT CFD Research, Inc:
Since its inception in 1987, CFD Research has worked with government agencies, businesses and academia to provide innovative solutions within the Aerospace & Defense, Biomedical & Life Sciences, and Energy & Materials industries. Over the years CFD Research has earned multiple national awards for successful application and commercialization of innovative component/system technology prototypes, multi-physics simulation software, multi-disciplinary analyses, and expert support services. CFD Research is an ISO9001:AS9100 registered company and is appraised at CMMI Level II for services. Learn more at www.cfd-research.com.
ABOUT Kalm Therapeutics, Inc.:
Kalm Therapeutics develops medicated patches with a controlled release cycle to treat atopic dermatitis. We offer a steroid free, natural alternative to the growing number of adults and children battling eczema.
For more information contact Chris Seibert at chrisseibert@kalmtherapeutics.com, or visit www.kalmtherapeutics.com.
